ANGX 3227

Drug Profile

ANGX 3227

Alternative Names: ANGX-3227

Latest Information Update: 04 Aug 2015

Price : $50

At a glance

  • Originator Angiogenix Inc
  • Class Antianaemics
  • Mechanism of Action Nitric oxide donors; Nitric oxide stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Sickle cell anaemia

Most Recent Events

  • 31 Oct 2006 This compound is still in active development for Sickle cell anaemia
  • 12 Jul 2004 Phase-II clinical trials in Sickle cell anaemia in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top